title: SARS transmission pattern in Singapore reassessed by viral sequence variation analysis.
abstract: BACKGROUND
  Epidemiological investigations of infectious disease are mainly dependent on indirect contact information and only occasionally assisted by characterization of pathogen sequence variation from clinical isolates. Direct sequence analysis of the pathogen, particularly at a population level, is generally thought to be too cumbersome, technically difficult, and expensive. We present here a novel application of mass spectrometry (MS)-based technology in characterizing viral sequence variations that overcomes these problems, and we apply it retrospectively to the severe acute respiratory syndrome (SARS) outbreak in Singapore.
  
  
  RESULTS
  The success rate of the MS-based analysis for detecting SARS coronavirus (SARS-CoV) sequence variations was determined to be 95% with 75 copies of viral RNA per reaction, which is sufficient to directly analyze both clinical and cultured samples. Analysis of 13 SARS-CoV isolates from the different stages of the Singapore outbreak identified nine sequence variations that could define the molecular relationship between them and pointed to a new, previously unidentified, primary route of introduction of SARS-CoV into the Singapore population. Our direct determination of viral sequence variation from a clinical sample also clarified an unresolved epidemiological link regarding the acquisition of SARS in a German patient. We were also able to detect heterogeneous viral sequences in primary lung tissues, suggesting a possible coevolution of quasispecies of virus within a single host.
  
  
  CONCLUSIONS
  This study has further demonstrated the importance of improving clinical and epidemiological studies of pathogen transmission through the use of genetic analysis and has revealed the MS-based analysis to be a sensitive and accurate method for characterizing SARS-CoV genetic variations in clinical samples. We suggest that this approach should be used routinely during outbreaks of a wide variety of agents, in order to allow the most effective control.
authors.affiliation: Genome Institute of Singapore, Singapore. liuj3@gis.a-star.edu.sg
authors.forename: Jianjun
authors.initials: J
authors.lastname: Liu
authors.forename: Siew Lan
authors.initials: SL
authors.lastname: Lim
authors.forename: Yijun
authors.initials: Y
authors.lastname: Ruan
authors.forename: Ai Ee
authors.initials: AE
authors.lastname: Ling
authors.forename: Lisa F P
authors.initials: LF
authors.lastname: Ng
authors.forename: Christian
authors.initials: C
authors.lastname: Drosten
authors.forename: Edison T
authors.initials: ET
authors.lastname: Liu
authors.forename: Lawrence W
authors.initials: LW
authors.lastname: Stanton
authors.forename: Martin L
authors.initials: ML
authors.lastname: Hibberd
mesh_terms: D004279:DNA, Viral / Q000032:analysis*; D004196:Disease Outbreaks; D014644:Genetic Variation; D006801:Humans; D013058:Mass Spectrometry; D016133:Polymerase Chain Reaction; D020641:Polymorphism, Single Nucleotide; D045473:Severe acute respiratory syndrome-related coronavirus / Q000235:genetics* / Q000472:pathogenicity; D045169:Severe Acute Respiratory Syndrome / Q000453:epidemiology / Q000635:transmission*
chemical_list: D004279:DNA, Viral
references.citation: Lancet. 2003 May 24;361(9371):1779-85
references.pmid: 12781537
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2542-7
references.pmid: 14983045
references.citation: Adv Biochem Eng Biotechnol. 2002;77:57-74
references.pmid: 12227737
references.citation: Science. 2004 Mar 12;303(5664):1666-9
references.pmid: 14752165
references.citation: N Engl J Med. 2004 Mar 25;350(13):1366-7
references.pmid: 15044654
references.citation: N Engl J Med. 2003 Dec 18;349(25):2468-9
references.pmid: 14681520
references.citation: Clin Chem. 2003 Dec;49(12):1976-80
references.pmid: 14633867
references.citation: J Clin Microbiol. 2004 Jan;42(1):347-50
references.pmid: 14715775
references.citation: Science. 2003 May 30;300(5624):1394-9
references.pmid: 12730500
references.citation: N Engl J Med. 2003 Dec 18;349(25):2431-41
references.pmid: 14681510
references.citation: J Clin Virol. 2003 Dec;28(3):233-8
references.pmid: 14522060
references.citation: Lancet. 2003 May 24;361(9371):1767-72
references.pmid: 12781535
references.citation: N Engl J Med. 2003 Jul 10;349(2):187-8
references.pmid: 12853594
references.citation: N Engl J Med. 2003 May 15;348(20):1967-76
references.pmid: 12690091
references.citation: Lancet. 2004 Jan 10;363(9403):99-104
references.pmid: 14726162
references.citation: Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3059-64
references.pmid: 12624187
references.citation: Clin Infect Dis. 2004 Jan 15;38(2):293-6
references.pmid: 14699465
references.citation: BMC Infect Dis. 2004 Sep 06;4:32
references.pmid: 15347429
references.citation: Emerg Infect Dis. 2004 Mar;10(3):413-8
references.pmid: 15109406
references.citation: Genome Res. 2004 Mar;14(3):398-405
references.pmid: 14993206
references.citation: J Gen Virol. 2003 Sep;84(Pt 9):2305-2315
references.pmid: 12917450
references.citation: Science. 2003 May 30;300(5624):1399-404
references.pmid: 12730501
references.citation: Lancet. 2003 Apr 19;361(9366):1319-25
references.pmid: 12711465